ARM 2022: Industry Briefs on Cell and Gene Therapies
One global network, the Alliance for Regenerative Medicine (ARM), represents 400 members from industry and academia in advocating for innovations and support of cell, gene, tissue-based advanced therapies.
At the ARM’s virtual 2022 Cell & Gene State of the Industry Briefing, two experts highlighted the sector’s progress in 2021 and welcomed industry experts to share their views on the promising future of regenerative medicine in 2022 and 2023. The speakers are:
It's free! Log in now to read
LATEST
Revolutionizing Treatment: ASGCT’s Clinical Trials Spotlight on Immunotherapy, Cancer Vaccines, and Auditory Diseases
2024-05-09
Advancing Health: ASGCT’s Clinical Trials Spotlight on Cell Therapy and Cell-Based Gene Therapy
2024-05-09
Infinitopes’ Article in Peer-Reviewed Journal Seeks to Unlock the Potential of Cancer Vaccines
2024-05-09
Profluent Achieves Human Genome Editing Milestone Using OpenCRISPR-1: The First AI-Generated, Open-Source Gene Editor
2024-05-08